Mesa Labs Announces Fourth Quarter and Fiscal Year 2026 Results
Mesa Labs reported FY26 revenue of $249.1 million, up 3.4% year-over-year, with adjusted operating income (excluding unusual items) rising 11.9% to $63.5 million. The company generated $39.6 million in free cash flow for the year, using proceeds to repay $14.7 million in debt during Q4, reducing the net leverage ratio to 2.11. While the Sterilization and Disinfection Control division saw strong 17.7% organic growth in Q4, the Biopharmaceutical Development division declined 29.9% due to export control shipping delays and commercial execution challenges.
Key figures
- Eps
- 1.21
- Revenue
- 249130000
- Guidance
- No specific FY27 guidance provided; CEO to provide rest of year guidance with H1 results.
- Revenue Yoy
- 3.4%
- Fcf
- 39581000
- Aoi margin
- 25.5%
- Fcf margin
- 15.9%
- Q4 revenue
- 63724000
- Fy net income
- 6712000
- Debt repaid q4
- 14700000
- Q4 revenue yoy
- 2.6%
- Fy net income yoy
- 440%
- Net leverage ratio
- 2.11
- Fy operating income
- 18511000
- Q4 operating income
- 2748000
- Fy operating income yoy
- 13.3%
- Q4 operating income yoy
- 87%
- Aoi excluding unusual items
- 63487000
- Core organic revenue growth fy
- 1.2%
- Core organic revenue growth q4
- -0.6%
- Aoi excluding unusual items yoy
- 11.9%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.